MarketCapExport financials
Mereo BioPharma Group plc (MREO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Mereo BioPharma Group plc Financial Statements 2025-2011 | MREO
Annual Financial Statements Mereo BioPharma Group plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.03 B | 2.55 B | 666 M | 754 M | 845 M | 64 M | 58.7 M | - | - | - | - | - | - | - | - |
Shares |
797 M | 740 M | 659 M | 603 M | 528 M | 17.9 M | 17.9 M | - | - | - | - | - | - | - | - |
Historical Prices |
2.55 | 3.44 | 1.01 | 1.25 | 1.6 | 3.58 | 3.28 | - | - | - | - | - | - | - | - |
Net Income |
- | - | - | - | - | -164 M | -34.8 M | -32 M | -38.8 M | -28.4 M | - | - | - | - | - |
Revenue |
- | - | - | - | 36.5 M | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | -936 K | 17.9 M | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | -16.3 M | -23.6 M | -22.7 M | -34.6 M | -24.6 M | - | - | - | - | - |
Operating Income |
- | - | - | -43.6 M | -20.9 M | -37.6 M | -39.5 M | -34.5 M | -45.3 M | -36.2 M | - | - | - | - | - |
EBITDA |
- | - | - | -43.6 M | -20.9 M | -37.6 M | -39.5 M | -34.5 M | -45.3 M | -33.5 M | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | 21.2 M | 15.9 M | 12.5 M | 10.7 M | 11.6 M | - | - | - | - | - |
General and Administrative Expenses |
- | - | - | - | - | 21.2 M | 15.9 M | 12.5 M | 684 K | 11.6 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in GBP currency
Quarterly Income Statement Mereo BioPharma Group plc
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
802 M | 800 M | 799 M | 784 M | 770 M | 712 M | 700 M | 627 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | - | - | - | - | - | - | 7.13 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
- | - | - | - | - | - | - | -9.91 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | - | - | - | - | - | -9.91 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in GBP currency
Main types of financial statements Mereo BioPharma Group plc MREOFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Mereo BioPharma Group plc plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Denali Therapeutics
DNLI
|
$ 19.67 | -6.15 % | $ 3.4 B |  USA |
 |
Amarin Corporation plc
AMRN
|
$ 11.56 | -5.63 % | $ 4.8 B |  Irlanda |
 |
Editas Medicine
EDIT
|
$ 2.53 | -6.99 % | $ 225 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
$ 28.28 | -9.88 % | $ 1.64 B | USA |
 |
Cue Biopharma
CUE
|
$ 18.09 | -8.82 % | $ 1.71 B | USA |
 |
Equillium
EQ
|
$ 1.32 | -5.71 % | $ 75.6 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
$ 1.68 | -11.84 % | $ 95.5 M | USA |
 |
Abeona Therapeutics
ABEO
|
$ 3.91 | -7.35 % | $ 207 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 21.23 | -1.12 % | $ 3.57 B | USA |
 |
Atossa Therapeutics
ATOS
|
$ 2.04 | -3.77 % | $ 17.6 M | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
- | -7.31 % | $ 49 M | USA |
 |
Five Prime Therapeutics, Inc.
FPRX
|
- | - | $ 1.77 B | USA |
 |
ADC Therapeutics SA
ADCT
|
$ 1.64 | -3.49 % | $ 208 M |  Schweiz |
 |
Harmony Biosciences Holdings
HRMY
|
$ 32.46 | -5.7 % | $ 1.87 B | USA |
 |
Ardelyx
ARDX
|
$ 2.98 | -9.57 % | $ 718 M | USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.43 | -38.22 % | $ 111 M | USA |
 |
Alector
ALEC
|
$ 2.08 | -8.99 % | $ 214 M | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.14 | -16.54 % | $ 61.2 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
$ 19.49 | -2.33 % | $ 6.11 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 3.65 | -10.1 % | $ 699 M |  Canada |
 |
Agenus
AGEN
|
$ 6.42 | -7.89 % | $ 191 M | USA |
 |
AbCellera Biologics
ABCL
|
$ 11.11 | -9.52 % | $ 3.32 B | Canada |
 |
Artelo Biosciences
ARTL
|
$ 2.12 | -8.77 % | $ 401 K | USA |
 |
Immatics N.V.
IMTX
|
$ 6.2 | -10.35 % | $ 759 M |  Germany |
 |
Aptevo Therapeutics
APVO
|
$ 1.24 | -9.49 % | $ 391 K | USA |
 |
Aligos Therapeutics
ALGS
|
$ 4.58 | -8.76 % | $ 45.3 M | USA |
 |
Aclaris Therapeutics
ACRS
|
$ 3.62 | -1.63 % | $ 444 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 26.8 | 0.32 % | $ 4.07 B | USA |
 |
Cellectar Biosciences
CLRB
|
$ 1.16 | -6.1 % | $ 3.03 M | USA |
|
Larimar Therapeutics
LRMR
|
$ 2.31 | -16.3 % | $ 192 M | USA |
 |
Biofrontera AG
BFRA
|
- | -8.24 % | $ 105 M | Germany |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
- | -6.97 % | $ 657 M | USA |
 |
Capricor Therapeutics
CAPR
|
$ 8.6 | -3.64 % | $ 400 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 27.55 | -1.68 % | $ 1.29 B | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
- | 1.68 % | $ 4.65 B |  China |
 |
Aquestive Therapeutics
AQST
|
$ 3.66 | -3.82 % | $ 391 M | USA |
 |
Jaguar Health
JAGX
|
$ 0.4 | -19.71 % | $ 933 K | USA |
 |
Arvinas
ARVN
|
$ 6.56 | -11.66 % | $ 465 M | USA |
 |
Cerus Corporation
CERS
|
$ 2.13 | -12.01 % | $ 406 M | USA |
 |
Beam Therapeutics
BEAM
|
$ 25.84 | -7.03 % | $ 2.56 B | USA |
 |
Moderna
MRNA
|
$ 241.1 | -6.69 % | $ 93.8 B | USA |
 |
Fortress Biotech
FBIO
|
$ 1.83 | -7.11 % | $ 51.1 M | USA |
 |
Inhibrx
INBX
|
$ 80.4 | -7.34 % | $ 3.79 B | USA |
 |
Entera Bio Ltd.
ENTX
|
$ 3.0 | -3.54 % | $ 139 M |  Israel |
 |
Flexion Therapeutics, Inc.
FLXN
|
- | - | $ 459 M | USA |
 |
Legend Biotech Corporation
LEGN
|
$ 22.52 | -1.1 % | $ 8.3 B | USA |
 |
CytomX Therapeutics
CTMX
|
$ 2.14 | -8.94 % | $ 295 M | USA |
 |
Krystal Biotech
KRYS
|
$ 300.08 | -3.46 % | $ 8.69 B | USA |
 |
Kura Oncology
KURA
|
$ 6.93 | -9.0 % | $ 608 M | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 1.45 | -7.67 % | $ 143 M | USA |